Artificial intelligence applications for the diagnosis of pulmonary nodules

This review evaluates the role of artificial intelligence (AI) in diagnosing solitary pulmonary nodules (SPNs), focusing on clinical applications and limitations in pulmonary medicine. It explores AI's utility in imaging and blood/tissue-based diagnostics, emphasizing practical challenges over technical details of deep learning methods.

AI enhances computed tomography (CT)-based computer-aided diagnosis (CAD) through steps like nodule detection, false positive reduction, segmentation, and classification, leveraging convolutional neural networks and machine learning. Segmentation achieves Dice similarity coefficients of 0.70-0.92, while malignancy classification yields areas under the curve of 0.86-0.97. AI-driven blood tests, incorporating RNA sequencing and clinical data, report AUCs up to 0.907 for distinguishing benign from malignant nodules. However, most models lack prospective, multiinstitutional validation, risking overfitting and limited generalizability. The "black box" nature of AI, coupled with overlapping inputs (e.g., nodule size, smoking history) with physician assessments, complicates integration into clinical workflows and precludes standard Bayesian analysis.

AI shows promise for SPN diagnosis but requires rigorous validation in diverse populations and better clinician training for effective use. Rather than replacing judgment, AI should serve as a second opinion, with its reported performance metrics understood as study-specific, not directly applicable at the bedside due to double-counting issues.